Op-Ed: The key to treating Alzheimer's disease may not be a drug

  • 📰 latimes
  • ⏱ Reading Time:
  • 31 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 16%
  • Publisher: 82%

Health Health Headlines News

Health Health Latest News,Health Health Headlines

Second Opinion: The path toward an Alzheimer's cure may not be a drug (via latimesopinion)

The lack of progress in developing an effective drug, or a combination of drugs, that will treat the disease once it arises suggests that we’ve been looking at this problem in the wrong way. Instead, effective therapies may require systemic approaches based on the principles of science-driven wellness. In my own search for answers, I learned that some important discoveries are being made.

— and based on correcting a patient’s unique deficiencies, assessed by analyzing their blood and other factors such as environmental toxins, diet, exercise and sleep., a team of Finnish and Swedish researchers found that non-drug-based approaches can work as interventions for older adults with elevated risk for dementia.also known as FINGER

To maintain brain health, we need to intervene with multimodal therapies as early as possible. The key will be determining the particular susceptibilities of each individual and designing a combination of interventions specific to that person.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

opinion raykwong educated_guest

opinion nice

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 11. in HEALTH

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Analysis: Rival treatments may help justify FDA gamble with Biogen Alzheimer’s drugData from clinical trials of three experimental Alzheimer's disease drugs expected to start emerging next year could help shed light on whether U.S. regulators were justified in their controversial approval of a Biogen Inc (BIIB.O) treatment without clear evidence that it works.
Source: Reuters - 🏆 2. / 97 Read more »